Built to last.
Ready to scale.

Boring Science LLC is a foundational data engineering firm operating at the intersection of high-dimensional multiomics, predictive molecular modeling, and automated research infrastructure.

We build the pipes
everyone else depends on.

We don't just solve biological puzzles — we build the industrial-grade infrastructure that makes biological data an asset rather than a liability. By providing a unified layer for data integrity, we empower partners across biopharma, sustainable agriculture, and environmental metagenomics to move from raw observation to predictable outcomes.

For the full technical picture — research areas, development tracks, and platform architecture — see our Science page.

$2.5T
AI-bio economy we are positioned within
2
revenue engines — SaaS packages & strategic consulting
sectors addressable with universal biological data infrastructure

Four reasons this
is the right bet.

01

Sector-Agnostic Utility

Our tech stack is built on universal biological data points — the same infrastructure that powers multiomics in drug discovery works for sustainable agriculture and environmental metagenomics. This is not a single-market bet. It is a platform play across the full $2.5T AI-bio economy.

02

Dual-Engine Revenue

We balance two complementary revenue streams: high-margin Software-as-a-Service through Boring Packages — containerized, reproducible pipelines deployed at scale — and high-impact strategic consulting through Boring Projects, embedded directly in partner research teams end-to-end.

03

De-risking Discovery

We bridge the simulation-to-implementation gap by replacing lucky hits with engineered leads. Integrating spatial multiomics, SE(3)-equivariant GNN scoring, AlphaFold3/Chai-1/Boltz-2 structure prediction, and pharmacovigilance-linked safety modeling into a single reproducible platform — built for rigor, not hype.

04

Rare Founding Expertise

Our founders combine Certified Pharmacovigilance Quality Review and Global Safety Database Operations with published multiomics, molecular biology, and translational research. Regulatory rigor meeting computational depth — a combination that is genuinely difficult to replicate and structurally defensible as a moat.

Addressing the full stack
of biological intelligence.

TAM
$2.5T
Total addressable AI-bio economy — drug discovery, multiomics, clinical genomics, digital health, sustainable agriculture, environmental metagenomics.
SAM
$85B
Serviceable addressable market — computational drug discovery, multiomics software, bioinformatics infrastructure, and pharmacovigilance analytics by 2030.
SOM
$800M
Near-term obtainable market — research institutions, pharma/biotech pilots, and clinical labs adopting reproducible computational infrastructure over a 5-year horizon.

Why not Schrödinger,
Recursion, or Benchling?

The competitive landscape is real — but fragmented. None of the incumbents solve the full-stack problem. We do.

Boring Science
Schrödinger
Recursion
Benchling
DNAnexus
Multiomics integration
Partial
Partial
SE(3)-equivariant GNN docking
Physics-based only
Pharmacovigilance + PGx
Reproducible GxP pipelines
Partial
Physics-constrained medical AI
Sector-agnostic deployment
Pharma only
Pharma only
R&D only
Genomics only
Published peer-reviewed validation
Partial

Schrödinger is physics-only and pharma-priced. Recursion runs phenotypic screens at scale but doesn't publish tools. Benchling manages lab data — it doesn't analyze it. DNAnexus stores genomics workloads but doesn't model biology. Boring Science does all five layers in one reproducible stack.

Research partnerships,
published evidence.

Boring Science's tools are grounded in active research collaborations with leading academic medical centers — not slide-deck promises. Our published and submitted work is the proof of concept.

6
Papers published or under review (2025)
4
Academic institutions with active collaborations
14
Proprietary software packages validated on real data
36
Max donors profiled in a single multiomics study
Research collaborators & institutional partners
uO
University of Ottawa
OHRI
Ottawa Hospital Research Institute
SU
Stanford University
CU
Columbia University Medical Centre

Two revenue engines.
High-margin from day one.

01
Boring Packages — SaaS
Subscription · Per-package or platform bundle
Research
From $499/mo
Individual lab or team access to 1–3 packages. Annual contract. Includes containerized deployment + updates.
Institutional
From $4,999/mo
Multi-user platform access across the full 14-package suite. Priority support, custom integration, SLA.
Enterprise
Custom
On-premise or private cloud deployment for pharma and diagnostics. Regulatory documentation, audit trails, ICH/CLIA compliance packaging.
Gross margin: ~85%
02
Boring Projects — Consulting
Project-based · Retainer
Pilot Engagement
From $25K
4–8 week scoped analysis project. Delivered output — reproducible pipeline, validated results, and a full technical report.
Embedded Research
From $15K/mo
Ongoing embedded partnership. Full-stack computational support across drug discovery, multiomics, or pharmacovigilance programs.
Regulatory Package
Custom
End-to-end pipeline development with GxP validation, regulatory submission formatting (ICH E2B, ACMG/AMP), and audit-ready documentation.
Gross margin: ~70%

Pre-seed round.
Actively raising.

Stage
Pre-Seed
Instrument
SAFE / Convertible
Use of Funds
See below
Deck
Available on request
45% — Engineering & platform development (bsagent, bsfep scale-out)
25% — GTM: pharma/biotech pilot partnerships & sales
20% — Regulatory validation & GxP compliance infrastructure
10% — Operations & legal

Ready to hear
the full roadmap?

Boring Science is actively engaging with investors, venture capital firms, and strategic partners who value engineering rigor over hype. Reach out to discuss our technical milestones, pipeline, and upcoming funding round — we share a full deck on request.

inquiries@boringscience.bio